ArticleScientific reports2026
Ganoderma lucidum spore oil with Ganoderma lucidum and Ganoderma sinense extracts (G2SO) shows antitumor and Immunomodulatory effects in mice.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Smart Polymer Nanoparticles: Targeting Macrophages/Fibroblasts and Modulating the Microenvironment for Rheumatoid Arthritis Therapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Ganoderma is a highly valued medicinal fungus, especially in Traditional Chinese Medicine (TCM). A formulation of Ganoderma lucidum spore oil and aqueous extracts from the fruiting bodies of Ganoderma lucidum and Ganoderma sinense (G2SO) has been developed as a functional formulation proposed to support immune function and tumor control. The aim of this study was to evaluate the antitumor activity and immunomodulatory effects of G2SO in mice. A tumor-bearing mouse model was established using 4T1 cells in BALB/c mice for antitumor evaluation. Immunomodulatory outcomes were evaluated in ICR mice after 30 days of oral administration. The results showed that the inhibition rate of G2SO on 4T1 tumors in the tumor-bearing mice was 35.31 ± 9.51%. Moreover, G2SO produced small but statistically significant enhancements of innate immune function in mice, including natural killer (NK) cell cytotoxicity and macrophage phagocytosis. Indices of adaptive immunity (hemolysin production and ConA-induced T-cell proliferation) were also increased, whereas LPS-stimulated cytokines tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and nitric oxide (NO) in RAW264.7 cells showed downward tendencies that were largely not significant. Overall, G2SO exhibits modest immunomodulatory activity together with measurable antitumor efficacy in vivo within the limits of the study design. These findings support further preclinical and clinical evaluation of G2SO as a functional formulation to support cancer prevention and immunomodulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.